Please use this identifier to cite or link to this item:
Title: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Authors: Larkin, James
Ascierto, Paolo A
Dréno, Brigitte
Atkinson, Victoria
Liszkay, Gabriella
Maio, Michele
Mandalà, Mario
Demidov, Lev
Stroyakovskiy, Daniil
Thomas, Luc
de la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Sovak, Mika A
Chang, Ilsung
Choong, Nicholas
Hack, Stephen P
McArthur, Grant A
Ribas, Antoni
metadata.dc.contributor.authoraffiliation: [Larkin,J] Royal Marsden Hospital, London.[Ascierto,PA] Istituto Nazionale Tumori Fondazione G. Pascale, Naples,Italy. [Dréno,B] Hôtel Dieu Place Alexis Ricordeau,Nantes,France. [Atkinson,V] Princess Alexandra Hospital, Woolloongabba, QLD,Australia. [Liszkay,G] National Institute of Oncology, Budapest, Hungary. [Maio,M] Azienda Ospedaliera Universitaria Senese, Siena,Italy. [Mandalà,M] Papa Giovanni XXIII Hospital, Bergamo,Italy. [Demidov,L] Blokhin Russian Cancer Research Center, Moscow,Russia. [Stroyakovskiy,D] Moscow City Oncology Hospital 62, Krasnogorsk, Russia. [Thomas,L] Centre Hospitalier Lyon Sud, Pierre-Bénite,France. [de la Cruz-Merino,L] Hospital Universitario Virgen Macarena, Seville, Spain. [Dutriaux,C] Hôpital Saint André, Bordeaux,France. [Garbe,C] University of Tübingen, Tübingen, Germany. [Sovak,MA; Chang,I; Choong,N; Hack,SP] Genentech, South San Francisco.[Ribas,A] Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.
Keywords: Indoles;Sulfonamides;Proto-oncogene proteins B-raf;MAP quinasa quinasa 1;Azetidines;Piperidinas;Sulfonamidas;Azetidinas
metadata.dc.subject.mesh: Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Aged
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azetines::Azetidines
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Mitogen-Activated Protein Kinase Kinases::MAP Kinase Kinase 1
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Piperidines
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins::Oncogene Proteins::Proto-Oncogene Proteins::raf Kinases::Proto-Oncogene Proteins B-raf
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Sulfones::Sulfonamides
Medical Subject Headings::Information Science::Information Science::Data Collection::Vital Statistics::Mortality::Survival Rate
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
Issue Date: 13-Nov-2014
Publisher: Massachusetts Medical Society
Citation: Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med.. 2014 ; 371(20):1867-76
Abstract: BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival. RESULTS The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy. CONCLUSIONS The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM number, NCT01689519.).
Description: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;
metadata.dc.identifier.doi: 10.1056/NEJMoa1408868
ISSN: 1533-4406 (Online)
0028-4793 (Print)
Appears in Collections:01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Larkin_CombinedVemurafenibCobimetinib.pdfArtículo publicado580 kBAdobe PDFView/Open
Larkin_CombinedVemura_protocol.pdfprotocol1,48 MBAdobe PDFView/Open
Larkin_CombinedVemura_disclosuresF.pdfdisclosure forms659,51 kBAdobe PDFView/Open
Larkin_combinedVemura_supp.pdfsupplementary appendix420,08 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons